This is a professional guideline developed by the China Anti-Cancer Association to standardize cancer pain assessment, diagnosis, and multimodal management across the disease trajectory.
Real-world retrospective cohort with substantial sample size and mature follow-up reporting clinically relevant survival outcomes, but lacks randomized control and prospective design needed for practice-changing or strong evidence.